Abstract. This research aimed to produce anti-claudin18.2 (CLDN 18.2)/anti-PD-L1 bispecific antibodies to enhance the therapeutic index and expand the responsive population of the parent anti-CLDN ...

DNA damage stress overload is a concept that describes the ability of a therapeutic regime to overwhelm the DNA damage response pathways in a cancer cell (1). This concept helps explain the efficacy ...

Abstract. Purpose: The high affinity receptor 1 (NTSR1) and its agonist, neurotensin (NTS), are correlated with tumor cell aggressiveness in most solid tumors. As chemoresistance and tumor ...

2019 Meetings Abstracts: AACR Special Conference on Modernizing Population Sciences in the Digital Age February 19–22, 2019; San Diego, CA Proceedings: AACR Annual Meeting 2019 March 29–April 3, 2019; ...

When determining the prognosis of a patient with a chronic disease, for example, a specific type of cancer, this quantity is usually expressed in terms of an overall survival (OS) probability. The ...

In 2003, Voskoglou-Nomikos (11) compared published drug activity for 31 cytotoxic cancer drugs where phase II trials, human xenograft, and mouse allograft responses were available for comparison for ...

Abstract. The BCR-ABL1–negative myeloproliferative neoplasms (e.g., essential thrombocythemia, polycythemia vera, and primary myelofibrosis) are a group of heterogeneous hematologic malignancies that ...

Neuroblastoma, the most common extracranial solid tumor in children, accounts for approximately 15% of pediatric cancer–related mortality. While 90% of patients with neuroblastoma with low and ...

Patients with FGFR2 -driven cancers derive limited benefit from pan-FGFRi due to multiple FGFR1–4-mediated toxicities and acquired FGFR2 resistance mutations. RLY-4008 is a highly selective FGFR2 ...

Abstract. Preclinical models have examined the pharmacologic and pharmacodynamic activities of an anti–vascular endothelial growth factor (VEGF) humanized, monoclonal antibody, bevacizumab, and/or its ...

AbstractEstrogen receptor–positive (ER+) breast cancer is not considered immunogenic and, to date, has been proven resistant to immunotherapy. Endocrine therapy remains the cornerstone of treatment ...

Immune checkpoint blockade therapy, one of the most promising forms of cancer immunotherapy, has been successful in multiple cancer types, including invasive urinary bladder cancer, the focus of this ...